Kodiak Sciences Inc
KOD9.840USD
+0.630+6.84%
Cierre 09/18, 16:00（ET）Cotizaciones retrasadas 15 min
519.77MCap. mercado
PérdidaP/E TTM
Más Datos de Kodiak Sciences Inc Compañía
Kodiak Sciences Inc. is a biopharmaceutical company. The Company has developed a new technology platform, the Antibody Biopolymer Conjugate (ABC) Platform, for retinal medicines. Its ABC Platform uses molecular engineering to merge the fields of protein-based and chemistry-based therapies. Its lead investigational medicine, tarcocimab, is a novel anti-vascular endothelial growth factor (anti-VEGF) antibody biopolymer conjugate under development for the treatment of high prevalence retinal vascular diseases, including diabetic retinopathy, the cause of blindness in working-age patients in the developed world, and wet age-related macular degeneration, the cause of blindness in elderly patients. Its second investigational medicine, KSI-501, is a bispecific antibody biopolymer conjugate targeting the pro-inflammatory cytokine interleukin-6 (IL-6) and VEGF. It is also developing a third investigational medicine, KSI-101, an unconjugated bispecific protein targeting IL-6 and VEGF.
Información de la empresa
Símbolo de cotizaciónKOD
Nombre de la empresaKodiak Sciences Inc
Fecha de salida a bolsaOct 04, 2018
Director ejecutivoDr. Victor Perlroth, M.D.
Número de empleados109
Tipo de seguridadOrdinary Share
Fin del año fiscalOct 04
Dirección1250 Page Mill Road
CiudadPALO ALTO
Bolsa de valoresNASDAQ Global Market Consolidated
PaísUnited States of America
Código postal94304
Teléfono16502810850
Sitio Webhttps://kodiak.com/
Símbolo de cotizaciónKOD
Fecha de salida a bolsaOct 04, 2018
Director ejecutivoDr. Victor Perlroth, M.D.
Ejecutivos de la empresa
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Mr. John A. Borgeson
Mr. John A. Borgeson
Chief Financial Officer, Executive Vice President, Secretary
Chief Financial Officer, Executive Vice President, Secretary
183.32K
+0.63%
Mr. Charles A. (Charlie) Bancroft
Mr. Charles A. (Charlie) Bancroft
Independent Director
Independent Director
25.95K
--
Mr. Robert A. Profusek, J.D.
Mr. Robert A. Profusek, J.D.
Lead Independent Director
Lead Independent Director
10.00K
--
Dr. Richard S. Levy, M.D.
Dr. Richard S. Levy, M.D.
Independent Director
Independent Director
1.00K
--
Dr. Taiyin Yang, Ph.D.
Dr. Taiyin Yang, Ph.D.
Independent Director
Independent Director
--
--
Dr. Victor Perlroth, M.D.
Dr. Victor Perlroth, M.D.
Chairman of the Board, Chief Executive Officer, Co-Founder
Chairman of the Board, Chief Executive Officer, Co-Founder
--
--
Dr. Felix J. Baker, Ph.D.
Dr. Felix J. Baker, Ph.D.
Independent Director
Independent Director
--
--
Dr. Bassil I. Dahiyat, Ph.D.
Dr. Bassil I. Dahiyat, Ph.D.
Independent Director
Independent Director
--
--
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Mr. John A. Borgeson
Mr. John A. Borgeson
Chief Financial Officer, Executive Vice President, Secretary
Chief Financial Officer, Executive Vice President, Secretary
183.32K
+0.63%
Mr. Charles A. (Charlie) Bancroft
Mr. Charles A. (Charlie) Bancroft
Independent Director
Independent Director
25.95K
--
Mr. Robert A. Profusek, J.D.
Mr. Robert A. Profusek, J.D.
Lead Independent Director
Lead Independent Director
10.00K
--
Dr. Richard S. Levy, M.D.
Dr. Richard S. Levy, M.D.
Independent Director
Independent Director
1.00K
--
Dr. Taiyin Yang, Ph.D.
Dr. Taiyin Yang, Ph.D.
Independent Director
Independent Director
--
--
Dr. Victor Perlroth, M.D.
Dr. Victor Perlroth, M.D.
Chairman of the Board, Chief Executive Officer, Co-Founder
Chairman of the Board, Chief Executive Officer, Co-Founder
--
--
Desglose de ingresos
Sin datos
Sin datos
Por negocio
Por región
Sin datos
Estadísticas de accionistas
Actualizado: sáb., 17 de may
Actualizado: sáb., 17 de may
Accionistas
Tipos de accionistas
Accionistas
Accionistas
Proporción
Baker Bros. Advisors LP
32.77%
Perlroth (Victor D)
5.10%
BlackRock Institutional Trust Company, N.A.
5.08%
Adage Capital Management, L.P.
3.89%
Acadian Asset Management LLC
3.73%
Otro
49.42%
Accionistas
Accionistas
Proporción
Baker Bros. Advisors LP
32.77%
Perlroth (Victor D)
5.10%
BlackRock Institutional Trust Company, N.A.
5.08%
Adage Capital Management, L.P.
3.89%
Acadian Asset Management LLC
3.73%
Otro
49.42%
Tipos de accionistas
Accionistas
Proporción
Hedge Fund
45.58%
Investment Advisor
18.13%
Investment Advisor/Hedge Fund
13.82%
Individual Investor
5.52%
Endowment Fund
1.31%
Research Firm
0.36%
Pension Fund
0.14%
Venture Capital
0.08%
Bank and Trust
0.08%
Otro
14.99%
Participación institucional
Actualizado: mar., 1 de jul
Actualizado: mar., 1 de jul
Periodo del informe
Número de instituciones
Acciones mantenidas
Proporción
Cambio
2025Q2
273
46.04M
87.25%
-8.67M
2025Q1
302
46.32M
87.78%
-8.84M
2024Q4
308
44.88M
85.29%
-7.98M
2024Q3
318
42.74M
81.24%
-12.36M
2024Q2
326
43.49M
82.78%
-12.58M
2024Q1
345
46.64M
88.83%
-7.18M
2023Q4
377
44.39M
84.60%
-13.12M
2023Q3
391
45.97M
87.64%
-8.18M
2023Q2
401
46.07M
88.00%
-6.85M
2023Q1
414
44.84M
85.66%
-7.92M
Ver más
Actividad de los accionistas
Nombre
Acciones mantenidas
Proporción
Cambio
Cambio %
Fecha
Baker Bros. Advisors LP
17.31M
32.81%
--
--
Mar 31, 2025
Perlroth (Victor D)
2.70M
5.11%
+527.00K
+24.31%
Mar 31, 2025
BlackRock Institutional Trust Company, N.A.
2.83M
5.37%
-21.30K
-0.75%
Mar 31, 2025
Adage Capital Management, L.P.
1.33M
2.51%
+186.18K
+16.34%
Mar 31, 2025
Acadian Asset Management LLC
1.95M
3.69%
+413.82K
+27.01%
Mar 31, 2025
The Vanguard Group, Inc.
1.69M
3.2%
+6.61K
+0.39%
Mar 31, 2025
ICONIQ Capital, LLC
1.27M
2.4%
+249.70K
+24.56%
Mar 31, 2025
TCG Crossover Management, LLC
1.15M
2.17%
--
--
Mar 31, 2025
State Street Global Advisors (US)
849.25K
1.61%
+18.08K
+2.18%
Mar 31, 2025
Geode Capital Management, L.L.C.
793.59K
1.5%
+24.90K
+3.24%
Mar 31, 2025
Ver más
ETFs relacionados
Actualizado: sáb., 6 de sep
Actualizado: sáb., 6 de sep
Nombre
Proporción
Invesco NASDAQ Future Gen 200 ETF
0%
iShares Biotechnology ETF
0%
Global X Russell 2000 Covered Call ETF
0%
Invesco Nasdaq Biotechnology ETF
0%
Fidelity Enhanced US All-Cap Equity ETF
0%
Invesco NASDAQ Future Gen 200 ETF
Proporción0%
iShares Biotechnology ETF
Proporción0%
Global X Russell 2000 Covered Call ETF
Proporción0%
Invesco Nasdaq Biotechnology ETF
Proporción0%
Fidelity Enhanced US All-Cap Equity ETF
Proporción0%
Dividendos
Un total de
0.00
USD se ha distribuido en dividendos durante los últimos 5 años.
Fecha
Dividendos
Fecha de registro
Fecha de pago
Fecha ex-dividendo
Sin datos
División de acciones
Fecha
Tipo
Relación
Sin datos
Fecha
Tipo
Relación
Sin datos
